Figure 3.
Probability of OS and EFS stratified by treatment regimes in pediatric tAML compared with de novo AML diagnosed from 2004. HSCT NEL was morphologically defined <5% blasts and no extramedullary blasts.
Probability of OS and EFS stratified by treatment regimes in pediatric tAML compared with de novo AML diagnosed from 2004. HSCT NEL was morphologically defined <5% blasts and no extramedullary blasts.
